Prof. Gribben's highlights from ASH 2016
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
The devastating effects of relapsed or refractory AML
How the treatment of ALL is changing
Improving the outcomes of transplantation with bispecific antibodies